



Press Release

Press Release

Press Release

Press Release

Press Release

Press Release

Press Release

Press Release

## Zydus Announces Settlement of Patent Litigation for Generic Revlimid® in U.S.

Ahmedabad, India, March 24, 2021

Cadila Healthcare Limited and its subsidiary Zydus Pharmaceuticals (USA) Inc. (Zydus Cadila) today announced that they have reached an agreement with Celgene Corporation (Celgene), a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY) relating to patents for REVLIMID® (lenalidomide). As part of the settlement, the Parties will file Consent Judgments with the United States District Court for the District of New Jersey that enjoin Zydus Cadila from marketing generic lenalidomide before the expiration of the patents-in-suit, except as provided for in the settlement.

### About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines. The group employs nearly 25,000 people worldwide, including 1,400 scientists engaged in R & D, and is dedicated to creating healthier communities globally. [www.zyduscadila.com](http://www.zyduscadila.com)

\*\*\*

For further information please contact :  
The Corporate Communications Department

**Cadila Healthcare Limited**  
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India.  
Phone : +91-079-71800000, +91-079-48040000 [www.zyduscadila.com](http://www.zyduscadila.com)  
CIN : L24230GJ1995PLC025878